Evidence map›Paper›PMID 40457089›Full record

ArticleAIDS and behavior2025

Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial.

Lisa Mills, Makhosazane Nomhle Ndimande-Khoza, Jennifer Velloza, Millicent Atujuna, Miria Chitukuta, Sybil Hosek, Hlukelo Chauke, Petina Musara, Nomvuyo Mangxilana, Prisca Mutero and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lisa MillsWits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street, Johannesburg, 2000, Republic of South Africa. lmills@wrhi.ac.za.ORCID http://orcid.org/0000-0002-6168-7008
Makhosazane Nomhle Ndimande-KhozaWits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street, Johannesburg, 2000, Republic of South Africa.
Jennifer VellozaDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Millicent AtujunaDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Scienced, University of Cape Town, Cape Town, South Africa.
Miria ChitukutaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Sybil HosekDepartment of Medicine, Center for Dissemination and Implementation Science, University of Illinois College of Medicine, Chicago, IL, USA.
Hlukelo ChaukeWits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street, Johannesburg, 2000, Republic of South Africa.
Petina MusaraUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Nomvuyo MangxilanaDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Scienced, University of Cape Town, Cape Town, South Africa.
Prisca MuteroUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Lerato Michelle MakhaleWits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street, Johannesburg, 2000, Republic of South Africa.
Thelma TauyaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Connie CelumDepartments of Global Health, Medicine, Epidemiology, University of Washington, Seattle, WA, USA.
Sinead Delany-MoretlweWits RHI, Faculty of Health Sciences, University of the Witwatersrand, 22 Esselen Street, Johannesburg, 2000, Republic of South Africa.
HPTN 082 study team

Funding

HIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Units for HIV/AIDS Clinical Trials NetworksU01AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI SANNE, IAN MATTHIAS · 2007 to 2011
$24.2M
NIAID NIH HHS U01 AI068619NIAID NIH HHS U01 AI069463NIAID NIH HHS UM1 AI069463
6 · The paper itself

Abstract

Oral PrEP effectiveness depends on consistent use during periods of potential HIV exposure, but adolescent girls and young women (AGYW) find this challenging. Data on PrEP use decision-making and alignment with risk among AGYW are limited. From 2016 to 2018, we conducted in-depth interviews with participants in HPTN 082, an open-label PrEP study in South Africa and Zimbabwe, to explore reasons for PrEP starts, stops, and restarts. Of 60 PrEP acceptors, 12 delayed acceptance, 15 used PrEP intermittently, 18 paused and restarted PrEP, and 13 permanently discontinued PrEP during 12-month follow-up. Perceived HIV vulnerability motivated PrEP start, but there was little evidence that fluctuating risk perception motivated prevention-effective use. PrEP stops were motivated by stigma, misconceptions and side effects; PrEP restarts were prompted by support from family, peers and clinic staff. Decision-making was related to social, gendered and normative influences, highlighting opportunities for psycho-educational support and multimedia campaigns to normalise HIV prevention.

Indexed as

Anti-HIV AgentsHIV InfectionsMedication AdherenceMotivationPatient Acceptance of Health CarePre-Exposure ProphylaxisAdolescentAdultDecision MakingFemaleHealth Knowledge, Attitudes, PracticeHumansInterviews as TopicQualitative ResearchSocial StigmaSouth AfricaAnti-HIV AgentsAdherenceAfricaHIVPre-exposure ProphylaxisSocial FactorsWomen

Identifiers

PMID40457089
PMCPMC12378742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.